Abstract: Provided herein are 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives of the general Formula I; and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X2 is N and Ring A, Ring B, Ring C, X1, X3, R1, L, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, such as e.g. cancer, e g. bladder cancer, brain cancer, breast cancer, cholangiocarcinoma, head and neck cancer, lung cancer, multiple myeloma, rhabdomyosarcoma, urethral cancer and uterine cancer. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 276 to 308; examples 1 to 30; examples A to E; tables CA to EE). An exemplary compound is e.g. 1-(3-(4-(4-(7-((3,5-dimethoxy phenyl) amino)quinoxalin-2-yl)-1H-pyrazol-1-yl)piperidine-1-carbonyl) azetidin-1-yl)prop-2-en-1-one (e.g. example 1).

Abstract: A method includes obtaining, by a management device, sub-interface information that includes a correspondence between an identifier of a first sub-interface of a first device and a first network slice identifier, a correspondence between an identifier of a second sub-interface of a second device and a second network slice identifier, and information indicating that the first sub-interface is directly connected to the second sub-interface, and determining, by the management device, a network slice topology based on the obtained sub-interface information.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Abstract: A single screw extrusion sprayer of a 3D printer includes a drive mechanism, a stir mechanism, and an extrusion mechanism. A side of the drive mechanism is connected to the stir mechanism to drive the stir mechanism to rotate, and another side of the drive mechanism is connected to the extrusion mechanism to drive the extrusion mechanism to rotate. The extrusion mechanism is connected to the stir mechanism to deliver stirred particles to the stir mechanism. The single screw extrusion sprayer has a compact structure and a light weight, and can be used in desktop 3D printers. The particle material can be melted for 3D printing.

Abstract: An acoustic emission probe positioning system, a test block for the system, and an application of the system are disclosed. The positioning system comprises a first test block and a second test block that are oppositely arranged and that define a non-closed test region. The first test block includes a first main portion and a first protruding portion that are connected to each other. The second test block includes a second main portion and a second protruding portion that are connected to each other. The first main portion and the second main portion are vertically opposite to each other, and the first protruding portion and the second protruding portion are opposite to each other left and right in a staggered manner. Multiple first probe storage holes are defined in the first main portion, and multiple second probe storage holes are defined in the first protruding portion.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Embodiments of the present disclosure provide an inverter vent and a loudspeaker having the same. Preferably, air flows within the inverted vent in a 360 degrees full-circumferential direction. This design can improve the efficiency of the loudspeaker, reduce the wind noise, and increase the bass ductility.

Abstract: A processor capable of changing redundant processing node comprises a plurality of processing nodes and a plurality of comparators. The plurality of processing nodes comprises a first processing node, a second processing node, and a third processing node, wherein the first processing node performs a first computation, the second processing node selectively performs the first computation or a second computation, and the third processing node performs the second computation. The plurality of comparators comprises a first comparator and a second comparator, wherein the first comparator connects to the first and second processing nodes to compare whether the results of the first computation performed by the first and second processing nodes are identical, and the second comparator connects to the second and third processing nodes to compare whether results of the second computation performed by the second and third processing nodes are identical.

Abstract: Disclosed are a hyaluronic acid-based zwitterionic polymer brush, a preparation method thereof, and the use thereof. The structure of the zwitterionic polymer brush is represented by formula (I), wherein n is an integer from 60-150, x is an integer from 589-686, and y is an integer from 125-230. The above-mentioned zwitterionic polymer brush can delay the pathological progress of osteoarthritis, promote cartilage regeneration, and even treat osteoarthritis and improve conditions such as the generation of abraded fragments of implants such as joints and related diseases triggered thereby, and can be combined with cartilage repairing materials to improve the frictional mechanical properties thereof for achieving better repair results. Moreover, the above-mentioned zwitterionic polymer brush can selectively bind to proteins in cartilage and has an excellent lubricating effect. The present invention has the advantages of simple method, convenient operation, easy purification, high yield, and the like.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Broadly neutralizing antibodies against HIV-1 which specifically bind to gp120 of HIV-1, a method of preparing such antibodies and the use thereof are provided.

Abstract: The present invention discloses a method for improving the blood compatibility of a material surface by using a controllable grafting technique. The method involves placing a monomer NVP, an RAFT reagent and a solvent acetonitrile in a container, adding an initiator AIBN, mixing the same uniformly, removing oxygen with liquid nitrogen, making the same react in an oil bath; after polymerization, adding liquid nitrogen to quench and stop the reaction, thus obtaining PVP-COOH; mixing the PVP-COOH with DCC and NHS; adding dry dichloromethane to the mixture in a nitrogen atmosphere, adding mercaptoethylamine, and making the same react in darkness at room temperature; obtaining a crude sample; dissolving the crude sample in water, and performing dialysis with deoxygenated water in darkness, and then obtaining HS-PVP by freeze-drying. An Au—S bond chemisorption method is used to controllably graft an anti-protein high-molecular polymer onto an Au surface.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1 and R2 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

Abstract: A medical macromolecular microsphere adsorbent for a blood perfusion apparatus and a preparation method thereof are provided. The polystyrene-divinylbenzene microspheres are graded by different pore sizes and specific surface areas, medically purified, and grafted by a bioactivity-controlled grafting technology. In the microsphere adsorbent, the volume ratio of microspheres with pore sizes of 1-10 ?m, 10-100 ?m and 100 ?m is 1:(1-10):(1-20), the content of residual monomers in the microsphere has O.D190-400 nm?0.03. The microsphere adsorbent not only can adsorb harmful micromolecules in blood but also can effectively adsorb harmful medium-molecules and macromolecules in blood, thereby meeting clinical application demands.